T Stamp Inc（IDAI）のニュースとイベントIDAIT Stamp Inc

Trust Stamp Signs Three-Year Agreement with BLIP

Trust Stamp announced the signing of a three-year technology services and data sovereignty agreement with BLIP Limited, a Nigerian technology provider delivering national-scale digital registration and certification platforms for the Nigerian government. Under the agreement, Trust Stamp will provide AI-Powered identity solutions for government programs in Nigeria, in a multi-million-dollar engagement. The deployment is expected to exceed one million enrolments in its first year of rollout, with the programs addressing a total population of tens of millions of people. The solution will be deployed in a customer-hosted environment, ensuring that all project data remains under Nigerian control and is processed in line with the Nigeria Data Protection Act 2023.

Trust Stamp Expands Strategic Partnership with ID Dataweb

Trust Stamp announced an expansion of its strategic partnership with ID Dataweb. ID Dataweb will expand its use Trust Stamp's biometric tokenization and identity fraud mitigation capabilities across its growing enterprise customer base.

Trust Stamp Files Patent Application for Medical Diagnostic System

Gareth Genner, CEO of Trust Stamp commented, "Prior to this we had a total of twenty seven issued or allowed patents and seven patents pending, covering a range of proprietary technologies encompassing AI, Biometrics and cryptography. On June 15, 2026 we filed U.S. Provisional Patent Application No. 64/091,057 entitled: "Medical Diagnostic Assurance System" for an LLM-based technology designed to avoid critical issues in medical diagnosis including confirmation bias amplification, and hallucinations that could cite invented data sources. Sycophantic behavior can undermine the reliability of LLM outputs in any use case, but in medical diagnosis, the consequences can be catastrophic. MDAS is intended to operate as a self-contained sovereign system with tokenization of patient identities, thereby protecting patient records from third-party access, for use only by qualified medical practitioners. MDAS does not provide a primary diagnosis but, using a three-model consensus, challenges and/or reinforces the medical practitioner's diagnosis using data flows that ensure that the model's research is conducted blind to that original diagnosis. We are currently negotiating a pilot program for MDAS and aim to have the technology live in Q1 of 2027."